Natarajan Sethuraman Sells 2,700 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) insider Natarajan Sethuraman sold 2,700 shares of the business’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $20.04, for a total value of $54,108.00. Following the completion of the transaction, the insider now directly owns 160,888 shares of the company’s stock, valued at approximately $3,224,195.52. The trade was a 1.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Natarajan Sethuraman also recently made the following trade(s):

• On Monday, November 11th, Natarajan Sethuraman sold 1,409 shares of Entrada Therapeutics stock. The stock was sold at an average price of $20.01, for a total transaction of $28,194.09.
• On Wednesday, October 16th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The shares were sold at an average price of $18.00, for a total value of $10,800.00.
• On Monday, September 9th, Natarajan Sethuraman sold 2,642 shares of Entrada Therapeutics stock. The stock was sold at an average price of $15.09, for a total value of $39,867.78.
• On Friday, September 6th, Natarajan Sethuraman sold 600 shares of Entrada Therapeutics stock. The shares were sold at an average price of $15.24, for a total transaction of $9,144.00.

Entrada Therapeutics Trading Down 4.6 %

NASDAQ:TRDA opened at $19.04 on Friday. The stock’s 50-day moving average is $16.62 and its 200-day moving average is $15.85. The stock has a market cap of $712.48 million, a P/E ratio of 11.97 and a beta of -0.26. Entrada Therapeutics, Inc. has a 1-year low of $10.75 and a 1-year high of $20.49.

Entrada Therapeutics (NASDAQ:TRDA) last announced its earnings results on Tuesday, August 13th. The company reported $1.55 EPS for the quarter, topping the consensus estimate of $0.65 by $0.90. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The firm had revenue of $94.69 million for the quarter, compared to the consensus estimate of $55.00 million. As a group, equities analysts forecast that Entrada Therapeutics, Inc. will post 1.07 EPS for the current year.

Analysts Set New Price Targets

TRDA has been the subject of several research analyst reports. HC Wainwright lifted their target price on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Oppenheimer boosted their price target on Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a research note on Wednesday, November 6th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. US Bancorp DE bought a new position in Entrada Therapeutics during the third quarter worth $42,000. Acadian Asset Management LLC acquired a new stake in Entrada Therapeutics during the 1st quarter worth about $79,000. SG Americas Securities LLC bought a new position in shares of Entrada Therapeutics in the 3rd quarter worth about $156,000. Allspring Global Investments Holdings LLC boosted its position in shares of Entrada Therapeutics by 427.6% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock valued at $209,000 after purchasing an additional 11,965 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Entrada Therapeutics by 34.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company’s stock valued at $226,000 after purchasing an additional 3,644 shares in the last quarter. Institutional investors and hedge funds own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.